Chronic hepatitis C: modern condition of the problem
https://doi.org/10.24884/1561-6274-2019-23-4-36-46
Abstract
Chronic hepatitis C (CHC) is one of the common chronic viral infections. Current advances in the treatment of chronic hepatitis C have allowed WHO to develop a Global health sector strategy on viral hepatitis for 2016-2021 with the purpose of its elimination by 2030. Antiviral drugs of new generations have therapeutic efficacy of more than 98% and wide indications for use. At the same time, there are special groups of patients in whom the choice of antiviral therapy regimen is limited and its effectiveness differs from the general population of patients with chronic hepatitis C. This review provides data on the epidemiology, pathogenesis, clinical manifestations of CHC, and current approaches to the treatment of the disease. Particular attention is paid to patients with extrahepatic manifestations of chronic HCV infection.
About the Authors
D. A. Lioznov
Pavlov First Saint Petersburg State Medical University; Influenza Research Institute A.A. Smorodintseva
Russian Federation
Russian Federation
Dmitry A. Lioznov - MD, PhD, DMedSci, Assistant professor First Pavlov SMU, Head of Department of Infectious Diseases and Epidemiology, Deputy Director for R Smorodintsev RII.
197022, 6/8 Lev Tolstoy st., St. Petersburg, Phone: 7(812) 338-60-40; 197376, prof. Popov street, 15/17, St. PetersburgN. V. Dunaeva
Unit of Somatic Pathology, Center for the Prevention and Control of AIDS and Infectious Diseases
Russian Federation
Russian Federation
Natalia V. Dunaeva - MD, PhD, assistant professor Head of the outpatient medical Department.
190103, 179 nab. Obvodny kannal, St.Petersburg, Phone: +7(921) 741-88-20
N. H. Chung
University of Medical and Pharmaceutical
Russian Federation
Russian Federation
Nguyen Huu Chung – MD,assistant of Department of Internal Medicine, extramural PhD student of the Research Institute of Epidemiology and Microbiology named after Pasteur.
Ho Chi Minh city, №217 Hong Bang st., Phone: (+84) 37-67-68-616
O. V. Gorchakova
Pavlov First Saint Petersburg State Medical University
Russian Federation
Russian Federation
Olga V. Gorchakova - MD, PhD, researcher at the laboratory of chronic viral infections SIC, assistant of the Department of infectious diseases and epidemiology.
197022, St. Petersburg, ul. L. Tolstoy 6/8,Phone +7(812)338-70-58
T. V. Antonova
Pavlov First Saint Petersburg State Medical University
Russian Federation
Russian Federation
Antonova Tamara Vasilyevna - MD, PhD, DMedSci, Prof, Department of infectious diseases and epidemiology.
197022, St. Petersburg, L. Tolstoy str. 6/8, Phone +7(812)338-70-58
References
1. WHO. Global hepatitis report 2017 [Электронный ресурс]. - 2017. - Режим доступа: http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/
2. Blach, S, Zeuzem S, Manns M et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The Lancet Gastroenterology & Hepatology 2016; 2 (3): 161-176
3. Lavenchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107-115
4. Everson GT, Towner WJ, Davis VN et al. Sofosbuvir With Vel-patasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized. Ann Intern Med 2015; 163 (11): 818-826
5. Bjoerkvoll B, Viet L, OI HS et al. Screening test accuracy among potential blood donors of HBsAg, anti-HBc and anti-HCV to detect hepatitis B and C virus infection in rural Cambodia and Vietnam. Southeast Asian. J Trop Med Public Health 2010; 41 (5): 1127-1135
6. Cavalcante LN, Lyra AC. Predictive factors associated with hepatitis C antiviral therapy response. World Journal of Hepatology 2015; 7 (12): 1617-1631
7. Kayali Z, Schmidt WN. Finally sofosbuvir: an oral anti-HCV drug with wide performance capability. Pharmacogenomics and Personalized Medicine 2014; 7: 387-398
8. Rao VB, Johari N, du Cros P et al. Hepatitis C serop-revalence and HIV co-infection in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Infect Dis 2015; 15 (7): 819-824
9. Anderson JC, Simonetti J, Fisher DG et al. Comparison of different HCV viral load and genotyping assays. J Clin Virol 2003; 28 (1): 27-37
10. Simmonds P, Bukh J, Combet C et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42 (4): 962-973
11. Smith DB, Bukh J, Kuiken C et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014; 59 (1): 318-327
12. Murphy DG, Willems B, Deschenes M et al. Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5’ untranslated region sequences. J Clin Microbiol 2007; 45 (4): 1102-1112
13. Murphy DG, Sablon E, Chamberland J et al. Hepatitis C virus genotype 7, a new genotype originating from Central Africa. J Clin Microbiol 2015; 53 (3): 967-972
14. Messina JP, Humphreys I, Flaxman A et al. Global Distribution and Prevalence of Hepatitis C Virus Genotypes. Hepatology 2015; 61 (1): 77-87
15. Chulanov VP, Pimenov NN, Mamonova ON et al. Chronic hepatitis C as a problem of public health in Russia today and tomorrow. Therapeutic Archive 2015; 11: 5-10
16. Pimenov NN, Vdovin AV, Komarova SV et al. Relevance and prospects for the implementation in Russia of a single Federal registry of patients with viral hepatitis B and C. Therapeutic archive; 2013 (11): 4-9
17. Kozlov VK, Stelmakh VV, Radchenko VG. HCV infection: A modern integrated treatment strategy. Manual for doctors. SPB, Dialect, 2008; 80
18. Lobzin SE. Viral hepatitis, SPB.: Foliant, 1999; 104
19. Nechaev VV, Ivanov AK, Panteleev AM. Socially significant infections. Part I. Monoinfection: tuberculosis, HIV infection, viral hepatitis, SPB.: Beresta LLC, 2011; 439
20. Zhdanov KV, Lobzin SE, Gusev YES, Kozlov KV. Viral hepatitis, SPb: Foliant, 2011; 304
21. Serov VV, Aprosina ZG. Chronic viral hepatitis, Moscow: Medicine, 2004; 384
22. Franco S, Barcons MG, BasagoitiFP et al. Characterization and evolution of NS5A quasispecies of hepatitis C virus genotype 1b in patients with different stages of liver disease. Journal of Medical Virology 2003, 71: 195-204
23. Lee MH, Yang HI, Lu SN et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012; 206 (4): 469-477
24. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J ViralHepat 2006; 13 (1): 34-41
25. Rehermann B, Bertoletti A. Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. J Hepatol 2015; 61 (2): 712-721
26. Kao JH, Ahn SH, Chien RN et al. Urgency to treat patients with chronic hepatitis C in Asia. J Gastroenterol Hepatol 2017; 32(5): 966-974. doi: 10.1111/jgh.13709
27. Rachel HW, Dusheiko G. Natural history of hepatitis C. Journal of Hepatology 2014; 61: 58-68
28. Kiyosawa K, Tanaka E, Sodeyama T, Furuta S. Natural History of Hepatitis C. Intervirology 1994; 37: 101-107
29. Mauss S, Rockstroh J, Wedemeyer H et al. Hepatology - A Clinical text book, 8-е изд., перераб. и доп., Hamburg: Medizin Fokus Verlag, 2017; 729
30. Bartenschlager R, Baumert TF, Bukh J et al. Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. Virus Research 2018; 248: 53-62
31. de Groen RA. Understanding the Innate Immune Response in Viral Hepatitis: Interferons and NKCells [Электронный ресурс] Erasmus University Rotterdam, 2017; Режим доступа: http://hdl.handle.net/1765/101848
32. Ishii S, Koziel MJ. Immune responses during acute and chronic infection with hepatitis C virus. Clinical immunology 2008; 128 (2): 133-147
33. Burke KP, Cox AL. Hepatitis C Virus Evasion of Adaptive Immune Responses- A Model for Viral Persistence. Immunologic research 2010; 47 (1): 216-227
34. Ascione A, Tartaglione T, Di Costanzo GG. Natural history of chronic hepatitis C virus infection. Dig Liver Dis 2007; 39(Suppl): S4-S7
35. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26: 34S-38S
36. Fattovich G, Giustina G, Degos F et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective followup study of 384 patients. Gastroenterology 1997; 112: 463-472
37. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349 (9055): 825-832
38. Planas R, Balleste B, Alvarez MA et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004; 40 (5): 823-830
39. Missiha SB, Ostrowski M, Heathcote EJ. Disease Progression in Chronic Hepatitis C: Modifiable and Nonmodifiable Factors. Gastroenterology 2008; 134 (6): 1699-1714
40. Sarin SK, Kumar M. Natural history of HCV infection. Hepatol Int 2012; 6 (4): 684-695
41. Cadieux G, Campbell J, Dendukuri N. Systematic review of the accuracy of antibody tests used to screen asymptomatic adults for hepatitis C infection. CMAJ Open 2016; 4(4): E737-E745
42. Fierer DS, Dieterich DT, Mullen MP et al. Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clin Infect Dis 2014; 58 (6): 873-879
43. Ha S, Totten S, Pogany L, Wu J, Gale-Rowe M. Hepatitis C in Canada and the importance of risk-based screening. Can Commun Dis Rep 2016; 42(3): 57-62
44. Mitchell AE, Colvin HM, Palmer R. Beasley Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology 2010; 51 (3): 729-733
45. Papatheodoridis GV, Tsochatzis E, Hardtke S, Wedemeyer H. Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review. Liver Int 2014; 34 (10): 1452-1463
46. Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nature medicine 2013; 19(7): 850-858
47. Zhevnerov CH, Antonova TV, Kovalev VA. Clinical and laboratory characteristics of chronic hepatitis C in the early stages of development. Scientific notes of St. Petersburg State Medical University. Acad. I.P Pavlova 2016; 23 (4): 45-49
48. Соринсон СН. Вирусные гепатиты. СПБ.: Теза, 1997, 326 [48. Sorinson CH. Viral hepatitis. SPB.: Teza, 1997, 326]
49. Sherman AC, Sherman KE. Extrahepatic manifestations of hepatitis C infection: navigating CHASM. Curr HIV/AIDS Rep 2015; 12(3): 353-361
50. Wong W, Denton M, Rennke HG, Lin J. Hepatitis C, proteinuria and renal insufficiency. Am J of Kidney Dis 2004; 44(5): 924-929
51. Milovanova SYu, Lopatkina TN, Kozlovskaya LV, Krasnova TN. Monoclonal antibodies to B-lymphocytes (rituximab) in the treatment of severe HCV-associated cryoglobulinemic glomerulonephritis. Ter archive 2007; 6: 69-72
52. Smirnov AV, Dobronravov VA, Sipovskiy VG, etc. A case of cryoglobulinem glomerulonephritis in hepatitis C. Nephrology 2007; 11 (4): 99-103
53. Smirnov AV, Trofimenko II. Fast-progressing nephritic syndrome in a patient with cryoglobulinemic vasculitis associated with chronic viral hepatitis. Nephrology 2010; 14 (1): 104-112
54. Smirnov AV, Dobronravov VA, Kayukov IG. Cardio-renal continuum: pathogenetic bases of preventive nephrology. Nephrology 2005; 9 (3): 7-15
55. Roccatello D, Fornasieri A, Giachino O et al. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am JKidney Dis 2007; 49(1): 69-82
56. Dobronravov VA, Dunaeva NV. Kidney damage and chronic viral hepatitis C. Nephrology 2008; 12 (4): 9-19
57. Kupin WL. Viral-Associated GN: Hepatitis C and HIV. Clin J Am Soc Nephrol 2016;12(8):1337-1342
58. Medvedev R, Ploen D, Hildt E. HCV and Oxidative Stress: Implications for HCV Life Cycle and HCV-Associated Pathogenesis. Oxid Med Cell Longev 2016;2016:9012580
59. Tutal E, Sezer S, Ibis A, Bilgic A, Ozdemir N, Aldemir D, Haberal M. The influence of hepatitis C infection activity on oxidative stress markers and erythropoietin requirement in hemodialysis patients. Transplant Proc 2010 Jun;42(5):1629-1636
60. Arciello M, Gori M, Balsano C. Mitochondrial dysfunctions and altered metals homeostasis: new weapons to counteract HCV-related oxidative stress. Oxid Med Cell Longev2013;2013:971024
61. Mustafa M, Hussain S, Qureshi S et al. Study of the effect of antiviral therapy on homocysteinemia in hepatitis C virus- infected patients. BMC Gastroenterol 2012;12:117
62. Lim T Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy. Hepat Med 2014;6:113-118
63. Gonzalez-Reimers E, Quintero-Platt G, Mart in-Gonzalez C, Perez-Hernandez O, Romero-Acevedo L, Santolaria-Fernandez F. Thrombin activation and liver inflammation in advanced hepatitis C virus infection. World J Gastroenterol 2016 May 14;22(18):4427-4437
64. Lopatkina TH. New in the treatment of chronic viral hepatitis [Electronic resource] The attending physician 2007; 1. Access Mode https://www.lvrach.ru/2007/01/4534659
65. Anderson JP, Tchetgen EJ, Lo Re V et al. Antiretroviral Therapy Reduces the Rate of Hepatic Decompensation Among HIV- and Hepatitis C Virus-Coinfected Veterans. Clin Infect Dis 2014; 58: 719-727
66. van der Meer AJ, Veldt BJ, Feld JJ et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308 (24):2584-2593
67. Washington DC Twenty-Five Years of Progress Against Hepatitis C: Setbacks and Stepping Stones. PhRMA 2014: 20
68. Manns MP, Pockros PJ, Norkrans G et al. Long-term clearance of hepatitis C virus following interferon a-2b or peginterferon a-2b, alone or in combination with ribavirin. J Viral Hepat 2013: 20: 524-529
69. Swain MG, Lai MY, Shiffman ML et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139:1593-1601
70. Geddawy A, IbrahimYE, Elbahie NM,Ibrahim MA. Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction. Journal of Translational Internal Medicine 2017; 5 (1): 8-17
71. Marinho RT, Barreira DP. Hepatitis C, stigma and cure. World Journal of Gastroenterology 2013; 19(40):6703-6709
72. Wikto SZ, Scott JD. What is the impact of treatment for hepatitis C virus infection? / Lancet 2017; 390 (10090): 107-109
73. Friedman RM, Contente S. Treatment of Hepatitis C Infections with Interferon: A Historical Perspective. Hepatitis Research and Treatment 2010; 1: P. 1-4
74. Sen G. Viruses and interferons. Annual Review of Microbiology 2001; 55: 255-281
75. Hoofnagl JH, Mullen KD, Jones DB et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. N Engl J Med 1986; 315:1575-1578
76. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989; 321(22): 1501-1506
77. Di Bisceglie AM, Martin P, Kassianides C et al. Recombinant interferon alpha therapy for chronic hepatitis C: a randomized, double-blind, placebo controlled trial. N Engl J Med 1989; 321:1506-1510
78. Chen CH, Yu ML. Hepatitis C Evolution of Interferon-Based Therapy [Electronic resource] Hepat Res Treat. 2010: 2010. Access mode: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990099/
79. Feld, JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436 (7053):967-972
80. Satoh S, Mori K, Onomura D et al. Ribavirin suppresses hepatic lipogenesis through inosine monophosphate dehydrogenase inhibition: Involvement of adenosine monophosphate-activated protein kinase-related kinases and retinoid X receptor a. Hepatology Communications 2017; 1(6): 550-563
81. Bodenheimer HCJr, Lindsay KL, Davis GL et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997; 26(2): 473-477
82. Dusheiko G, Main J, Thomas H et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled trial. J Hepatol 1996; 25,(5): 591-598
83. McHutchison JG, Everson GT, Gordon SC et al. nterferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-1492
84. Poynard T, Marcellin P, LeeSS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C. Lancet 1998; 352(9138):1426-1432
85. Heathcote EJ, Shiffman ML, Cooksley WG et al. Peginter-feron alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343(23): 1673-1680
86. Lindsay KL, Trepo C, Heintges T et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34(2): 395-403
87. Reddy KR, Wright TL, Pockros PJ et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33(2):433-438
88. Zeuzem, S, Feinman SV, Rasenack J et al. Peginter-feron alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343(23):1666-1672
89. Zeuzem S. Do differences in pegylation of interferon alfa matter? Gastroenterology 2010; 138(1):34-36
90. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347(13):975-982
91. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358(9286): 958-965
92. Pawlotsky JM, Roudot-Thoraval F, Bastie a et al. Factors effecting treatment responses to interferon-alpha in chronic hepatitis C. J Infect Dis 1996; 174(1): 1-7
93. Berg T, von Wagner M, Nasser S et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130(4):1086-1109
94. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005; 41: 275-279
95. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology 2007;46:1688-1694
96. Davis GL, Wong JB, McHutchison JG et al.Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38: 645-652
97. Ferenci P, Fried MW, Shiffman ML et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin. J Hepatol 2005; 43: 425-433
98. Jensen DM, Morgan TR, Marcellin P et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43:954-960
99. Rosen H. Clinical practice. Chronic hepatitis C infection. N Engl J Med 2011;364(25):2429-2438
100. Hadziyannis SJ, Sette HJ, Morgan TR et al. Peginterferon alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140(5):346-355
101. Manns MP, Foster GR, Rockstroh JK. The way forward in HCV treatment - finding the right path. Nature Reviews Drug Discovery 2007;6:991-1000
102. EASL. Recommendations on Treatment of Hepatitis C 2014 / European Association for the Study of the Liver (EASL). J Hepatol 2014;61(2):373-395
103. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006; 55(9):1350-1359
104. Ghany MG, Nelson DR, Strader DB et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver. Hepatology 2011; 54: 1433-1444
105. Hezode C, Forestier N, Dusheiko G et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-1850
106. Kwo PY Lawitz EJ, McCone J et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 triali. Lancet 2010; 376: 705-716
107. McHutchison JG, Everson GT, Gordon SC et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360:1827-1838
108. McHutchison JG, Manns MP, Muir AJ et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-1303
109. Poordad F, Bruno S, Manns MP et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206
110. Sherman KE, Flamm SL, Afdhal NH et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-1024
111. Hezode C. Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice. Liver International 2012; 32: 32-38
112. Maasoumy B, Port K, Markova AA et al. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS One 2013; 8(2):e55285
113. Alexopoulou A, Karayiannis P. Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals. Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology 2015; 28(1):55-65
114. Lawitz E, Mangia A, Wyles D et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-1887
115. Schinazi RF, Shi J, Whitaker T. “Sofosbuvir (Sovaldi): The First-in-Class HCV NS5B Nucleotide Polymerase Inhibitor”. Innovative Drug Synthesis. / под общ. ред. J.J. Li, D.S. Johnson . NJ, USA: John Wiley & Sons 2015:341 с
116. Alberti A, Piovesan S. The evolution of the therapeutic strategy in hepatitis C: Features of sofosbuvir and indications. Digestive and Liver Disease 2014;46 (Suppl 5): S174-S178
117. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138(2): 447-462
118. Karageorgopoulos DE, El-Sherif O, Bhagani S, Khoo SH. Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection. Curr Opin Infect Dis 2014; 27(1):36-45
119. Koff R. Review article: the efficacy and safety of sofos-buvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2014;39(5): 478-487
120. Gane EJ, Roberts SK, Stedman CA et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376:1467-1475
121. Alric L, Plaisier E, Thebault S et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J of Kidney Dis 2004 Apr; 43(4): 617-623
122. Dunaeva NV, Gezey MA, Kolpashchikova EY et al. Experience in the treatment of pegylated interferon alpha and ribavirin of chronic hepatitis C, complicated by the development of mixed cryoglobulinemia. Herald of Novgorod State University 2017; 106 (8): 75-82
123. Ignatova TM, Kozlovskaya LV, Gordovskaya NB et al. Cryoglobulinemic vasculitis associated with hepatitis C virus: 20 years of treatment experience. Therapeutic Archives 2017; 89 (5): 46-52
124. EASL Recommendations on Treatment of Hepatitis C 2015. European Association for the Study of the Liver. J of Hepatology 2015 Jul; 63(1): 199-236
125. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected withhepatitis C virus. Hepatology 2015 Sep;62(3):932-954
126. AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis 2018 Oct 30;67(10):1477-1492
127. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol 2018 Aug;69(2):461-511
128. KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney International Supplements 2018;8:91-165
129. Dunaeva NV, Karev VE, Vorobyova OA et al. Antiviral therapy for chronic hepatitis C, complicated by systemic cryoglobulinemic vasculitis. Journal of Infectology 2016; 8 (2): 40-47
130. Li T, Qu X Guo X Wang X Wang L. Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis. Liver Int 2017 Jul;37(7):974-981
131. Munoz-Gomez R, Rincon D, Ahumada A et al. Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience. J ViralHepat 2017 Jun;24(6):464-471
132. Fernandez I, Munoz-Gomez R, Pascasio JM et al. Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C. J Hepatol 2017 Apr;66(4):718-723
133. Dunaeva NV, Kolpashchikova EY Romanova SY et al. Therapy with direct antiviral drugs of chronic hepatitis C, complicated by the development of mixed cryoglobulinemia. Journal of Infectology 2018; 10 (4): 53-63
134. Santoriello D, Pullela NK, Uday KA, et al. Persistent Hepatitis C Virus-Associated Cryoglobulinemic Glomerulonephritis in Patients Successfully Treated With Direct-Acting Antiviral Therapy. Kidney Int Rep 2018 Apr 10;3(4):985-990
135. Suda G, Ogawa K, Morikawa K, Sakamoto N. Treatment of hepatitis C in special populations. J Gastroenterol 2018 May;53(5):591-605
136. Corson M, Moch A, Saab S. Hepatitis C Virus Treatment in Patients With Chronic Kidney Disease and in Kidney Transplant Recipients. Gastroenterol Hepatol (N Y) 2018 May;14(5):280-285
137. Goldberg DS, Abt PL, Reese PP; THINKER Trial Investigators. Transplanting HCV-Infected Kidneys into Uninfected Recipients. N Engl J Med 2017 Sep 14;377(11):1105
138. Kamalkiran M, Ravikiran V, Shashidhar C, Prasad KVR, Yeldandi V. Kidney Transplantation from a Hepatitis C Virus-positive Donor to a Hepatitis C Virus-negative Recipient. Indian J Nephrol 2018 Nov-Dec;28(6):488-489
139. Durand CM, Bowring MG, Brown DM et al. Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial. Ann Intern Med 2018 Apr 17;168(8):533-540
140. Reese PP, Abt PL, Blumberg EA et al. Twelve-Month Outcomes After Transplant of Hepatitis C-Infected Kidneys Into Uninfected Recipients: A Single-Group Trial. Ann Intern Med2018 Sep 4;169(5):273-281
141. Eckman MH, Woodle ES, Thakar CV, Paterno F, Sherman KE. Transplanting Hepatitis C Virus-Infected Versus Uninfected Kidneys Into Hepatitis C Virus-Infected Recipients: A Cost-Effectiveness Analysis. Ann Intern Med 2018 Aug 21;169(4):214-223.
Review
For citations:
Lioznov D.A., Dunaeva N.V., Chung N.H., Gorchakova O.V., Antonova T.V. Chronic hepatitis C: modern condition of the problem. Nephrology (Saint-Petersburg). 2019;23(4):36-46. (In Russ.) https://doi.org/10.24884/1561-6274-2019-23-4-36-46
Views:
7048
Email this article 